RAPS Regulatory Affairs Certification – Drugs (RAC‑Drugs) Practice Test

These questions are part of the practice quiz. Start practicing

• What is the significance of "scientific advice" from regulatory agencies?
• What is the role of the FDA's Center for Drug Evaluation and Research (CDER)?
• Which term BEST describes a multidimensional combination of input variables and process parameters assuring quality?
• When a raw material is received and put into quarantine, what information must be included on the sample containers?
• In the context of drug regulations, what does the term "orphan drug" refer to?
• Which component is essential for an investigational new drug application?
• Which of the following is not the sponsor's responsibility concerning investigational products?
• What constitutes a "serious adverse event"?
• Investigational combination products that include a device constituent part are subject to which provision of 21 CFR part 820?
• What would NOT be a consequence of a change in FDA policy?
• Which of the following steps is critical in confirming quality for batch release?
• What does "orphan drug" designation refer to?
• What are "excipients" in drug formulation?
• What one major factor is reviewed by the Institutional Review Board (IRB)?
• What process should a sponsor use to gain permission from FDA for an ANDA that differs from the RLD?
• Which factor typically influences the decision for a drug's approval?
• What should be the first course of action when preparing for a pre-submission meeting with a health authority?
• What is the role of the Institutional Review Board (IRB)?
• Which of the following is NOT a focus of medicinal chemistry?
• Which aspect does the clinical trials data relate to in a drug submission?
• Which agencies initiated a pilot program "PARALLEL SCIENTIFIC ADVICE (HUMAN MEDICINAL PRODUCTS)" for scientific discussions during medicinal product development?
• What is "accelerated approval" by the FDA?
• When are adverse events reported in clinical trials?
• What is the definition of an "adverse drug reaction"?
• Which factor is typically not a reason for a drug to receive "fast track designation"?
• What regulatory aspect is linked to the utilization of a single DLP in a PBRER?
• What is the significance of post-marketing surveillance?
• Which of the following would typically NOT be included in a PBRER?
• In the context of regulatory affairs for drugs, which testing is most emphasized for assessing safety profiles?
• Which of the following is NOT a role of the FDA Office of Combination Products?
• What element is essential for ensuring a successful drug marketing authorization process?
• What is the typical duration for implementing changes after receiving a complete response request from the FDA on a BLA?
• In regulatory affairs, what does CTD provide to applicants?
• Which of the following statements accurately reflects the purpose of human factors validation?
• From which source do the consistent adverse drug reaction terms used for product labeling originate?
• What is one of the key components of drug labeling?
• Which of the following is directly related to the stability of a product?
• What is essential to achieve during clinical trials to ensure participant safety?
• What does an IND application allow?
• In pharmaceuticals, what does "formulation" mean?
• You are a manufacturer in the US, and you discover that your company's top selling product has been used off-label. What is the MOST appropriate next step?
• What is a recommended argument against scheduling Dextromethorphan as a controlled substance?
• What should a regulatory professional do when management insists on including a claim in labeling, but the FDA proposes a more restrictive claim?
• What is the importance of pharmacovigilance?
• What is the purpose of a "preclinical study"?
• Before starting a pharmaceutical clinical trial, what must the clinical investigator obtain?
• Why is it important for sales materials to include appropriate indications?
• What is the main purpose of an "investigator's brochure"?
• If there is a slight change in drug substance storage temperature, what is the recommended action to take?
• What type of information is typically found in a drug's section 505(b)(2) application?
• In a single ANDA for an oral solid dosage form, which variation can be included assuming other parameters remain unchanged?
• For sites conducting clinical trials in the EU, what specific labeling requirement must be met?
• What key information is typically found in a common technical document?
• What should a biotechnology company submit with the Marketing Authorisation Application dossier for a follow-on biologic?
• What is a radiolabeled drug?
• A manufacturer wants to gain approval for an OTC product already approved for a different indication by a competitor in a Reference Member State. Which filing is required?
• What is the primary aim of "phase IV" clinical trials?
• What primary information must be included in an IND submission regarding the drug's composition?
• What is the purpose of a Clinical Study Report (CSR)?
• What defines a "new molecular entity" (NME)?
• During which phase are large-scale studies conducted to confirm a drug’s efficacy?
• What is the function of the NDA process in drug approvals?
• For a new drug product, what is an essential prerequisite for a successful registration process?
• What should be discussed in submission documents if the Scientific Advice from the CHMP is not followed?
• What is characterized as an "exploratory investigational new drug" (IND)?
• What does "clinical significance" denote in the context of treatment effects?
• Who has the responsibility for signing the declaration statement in the Marketing Authorisation Application in the EU?
• Which U.S. agency makes the first assessment of a new drug's potential for addiction and/or abuse?
• What is the most appropriate next regulatory step after a clinical trial for a medicinal product has been finalized in several European countries?
• What is included in safety reporting during clinical trials?
• What is a correct duty of the Qualified Person (QP) responsible for batch release?
• How do pharmaceutical benefit managers help control healthcare costs?
• What type of information is included in the Official Journal of the European Union?
• What does a "label comprehension study" analyze?
• What is typically advised when conducting bioequivalence studies for a generic product?
• Which of the following statements regarding European scientific guidelines is correct?
• What does the New Drug Application (NDA) signify?
• In what scenario would a firm not need to submit a new NDA?
• Under what circumstances might a clinical investigator file for compassionate use of a product?
• In the context of clinical trials, what does the term "sponsor" refer to?
• What is the goal of a "clinical efficacy endpoint"?
• Which of the following would require a Type A meeting with the US FDA?
• For biological drug products regulated by CBER, how many days does the FDA hold a Type C meeting after receiving a sponsor's meeting request?
• What claim would classify an apple as a drug?
• What type of validation can a firm conduct to assure effective process validation for a new medicinal product?
• For a non-innovative drug authorized in one member state, what is the BEST strategy for extending the license in other member states?
• What is the best action for a regulatory professional who discovers operational difficulties during the review of a clinical trial protocol?
• Which of the following factors is NOT considered when performing a risk assessment in drug development?
• Which step would NOT be included in the verification that an advanced therapy medicinal product manufacturing equipment adheres to user specifications and GMP requirements?
• In which module of the CTD is the quality information of a medicinal product displayed?
• Which statement is acceptable for advertising an approved arthritis medication?
• What can be the impact of failing to conduct human factors studies as mandated by the FDA?
• FDA CDER encourages submission of a human factors validation protocol for review. What is the most appropriate mechanism for the feedback?
• What is a required record when a prescription drug is sold by a manufacturer to a chain pharmacy's warehouse?
• What is the primary goal of regulatory professionals in negotiations with the FDA about product labeling?
• What does an Abbreviated New Drug Application (ANDA) aim to demonstrate?
• What essential content must be included on the label for a study drug in the EU?
• What advantage does a common technical document format provide to regulatory submissions?
• What does "surrogate endpoint" refer to in clinical trials?
• Which documentation is essential for a follow-on biologic product?
• What is the purpose of the Pre-Submission Consultation program?
• Which statement about biosimilars is NOT correct?
• Which statement accurately captures the essence of clinical significance?
• Which of the following could form part of the procedures for a non-interventional imposed PASS?
• Which statement is false regarding orphan drug designation in the US?
• According to ICH Q10, which of the following statements about implementing a Pharmaceutical Quality System (PQS) is EXCEPT?
• What is the exclusivity period for a new chemical entity (NCE) in the U.S.?
• Which statement best describes a primary focus of PBRERs?
• What is the primary purpose of having a single Data Lock Point in a PBRER?
• What is a critical factor when preparing for a pre-submission meeting regarding drug registration?
• Blood Center ABC plans to manufacture and sell blood products. What must they do upon starting operations?
• What does CTD stand for in the context of drug application submissions?
• What is the purpose of a risk evaluation and mitigation strategy (REMS)?
• A company developing a cell and gene therapy that is a combination product should submit which type of application?
• What is the aim of a drug's therapeutic index?
• Which of the following is a key factor considered in determining expedited review for a new therapy?
• What type of drug is typically addressed by the Mutual Recognition Procedure (MRP)?
• What does "drug labeling" provide?
• Which statement is TRUE regarding expedited programs for regenerative medicine therapy products?
• What is one of the main goals of clinical trials?
• Which of the following is FALSE regarding regulatory meetings between CBER and sponsors of biological products?
• One of the roles of a pharmaceutical benefit manager is to:
• What is the primary role of the Drug Enforcement Administration (DEA)?
• What should a company do FIRST in response to a regulatory authority's request for product testing compliance with new regulations?
• What did the FDA announce in its 2017 Guidance regarding Human Cells, Tissues, and Cellular Products?
• What does "informed consent" ensure in clinical trials?
• Why is continuous monitoring vital in clinical trial safety reporting?
• What is the primary purpose of the ICH?
• What does "market authorization" signify in drug regulation?
• According to ICH guidelines, which adverse drug reaction must be reported expeditiously?
• What is the primary purpose of a Phase I clinical trial?
• In which scenario might expedited review processes be employed?
• In a situation where production records show a theoretical yield exceeding limits, what should be the investigation's recommendation?
• Which organization is primarily responsible for regulating the safety of drugs in the United States?
• What is the next step if a serious adverse event of Grade 4 is confirmed for an investigational drug?
• Which organization typically utilizes the services of a pharmaceutical benefit manager?
• What are the primary responsibilities of regulatory affairs professionals?
• What should a variation for a complex manufacturing change include?
• What is the role of the Office of New Drugs (OND) at the FDA?
• What role does a regulatory professional play in the sales department’s preparation of materials?
• What is the best course of action for a regulatory professional when contacted by an FDA reviewer with questions about a submitted 510(k) application?
• What could be a consequence of providing no indications in sales materials?
• What do "Good Manufacturing Practices" (GMP) ensure?
• Which of the following is NOT a reason to file an OMOR?
• If a manufacturer submits a Type IA variation application for a product authorized through the Mutual Recognition Procedure, what could happen within 30 days?
• What is typically assessed during Phase III clinical trials?
• How many days after FDA approval of an NDA must the sponsor submit the content of labeling in SPL format?
• What is the BEST approach for a company developing a new line of products in an unfamiliar area?
• What should be included in a regulatory submission that demonstrates adherence to applicable regulations and standards?
• What is one main purpose of Good Manufacturing Practices?
• How does the FDA define "biologics"?
• What term describes a product that is similar to a biologic already approved by a regulatory agency?
• What is the importance of understanding the environmental characteristic of product stability?
• Who is required to validate a drug's stability data as part of a marketing application?
• In the EU, which type of documentation should NOT be included in Module 1 of a submitted dossier?
• Which of the following is a key element in the stability studies for a pharmaceutical product?
• Before launching a product in a new country, which resource should be examined FIRST?
• According to EMA Variation Guideline, what type of variation is required to be notified immediately upon implementation?
• What does the term "pharmaceutical equivalence" mean?
• How can a company obtain faster Marketing Authorization for a generic, non-biologic product after the data exclusivity period has ended?
• When developing a global drug product, which environmental characteristic is most crucial to consider?
• What is a correct statement regarding the Periodic Benefit-Risk Evaluation Report (PBRER)?
• In the context of human factors studies, what does FDA require for demonstrating safety and efficacy?
• In the provided safety database for an anti-hypertensive drug, which long-term ICH data requirement has not been met?
• A pharmaceutical company is developing a new drug. Which scenario would most likely require extensive safety pharmacology studies?
• What action would the FDA consider as obstructing an inspection?
• What does a clinical trial protocol outline?
• How is a "generic drug" defined?
• What opportunity does Regulation EC 469/2009 provide?
• What is the primary requirement for the lot release of biologics?
• Which resource can provide valuable insights into best practices for drug development?
• In a recent incident involving a prescription migraine medication, which claim made in a promotional video would be considered false or misleading?
• Which phase of clinical trials primarily focuses on safety?
• Which responsibility is NOT typically assigned to a sponsor?
• What action will restart the review clock after receiving a non-approval letter for a BLA?
• What is "medicinal chemistry" primarily concerned with?
• In which scenario would the FDA likely require a human factors validation study?
• Which title of Directive 2001/83/EC, as amended, refers to the supply of samples?
• What is typically assessed during a Phase I clinical trial?
• In preparing a presentation for senior management in regulatory affairs, which topic is MOST important to cover?
• When preparing a PBRER, what should the regulatory professional ensure regarding the DLP?
• During the planning phase for scientific advice with EMA, what is the first event that occurs?
• What is "bioequivalence"?
• Which term does NOT describe biosimilars?
• Which of the following statements best describes the purpose of a radiolabeled drug?
• What is the MOST appropriate first step for Company X to gather information about Company Y for potential acquisition?
• What is the primary role of a pharmaceutical benefit manager (PBM)?
• Which statement about an Authorized Generic Drug is NOT correct?
• How many days does the FDA have to file, or refuse to file, an NDA after receipt?
• What is a potential benefit of using radiolabeled drugs in medical diagnostics?
• What should a regulatory affairs professional consider when assessing compliance for a new therapeutic product?
• What constitutes a key function of excipients in drug formulation?
• What is the least likely action OPDP will take in response to a promotional communication?
• What does "blinding" aim to achieve in clinical trials?
• What is the MOST appropriate action for a regulatory professional if a revised USP monograph involves a minor change during an NDA review?
• What is evaluated in a cost-effectiveness analysis?
• What is the minimum duration of continuous use that requires carcinogenicity testing for pharmaceuticals?
• Which toxicity test is mandatory and cannot be waived during preclinical investigations of a new chemical entity?
• In the assessment of a manufacturing process change for a cellular therapy product, what indicates that the pre-change and post-change products are comparable?
• Which of the following relates to the concept of a clinically meaningful outcome?
• What does the term "adverse event" refer to in clinical trials?
• Which of the following changes to an approved NDA can be implemented prior to FDA approval?
• In drug reformulation, what is a critical factor for ensuring compliance with regulations?
• If a company developing a drug-device combination product is uncertain about its marketing application submission, what should they first submit?
• What document is essential when submitting a variation for a change in manufacturing process?
• What does the term "labeling" exclude in drug regulation?
• What term is defined as reported information on a possible causal relationship between an adverse event and a drug?
• Which of the following is false regarding meeting minutes for formal meetings related to biological products regulated by CBER?
• When evaluating the regulatory framework for a drug in another country, what should be the initial focus?
• If a commercial stability batch testing yields out-of-specification results, what is the best action to take?
• What is the main purpose of an end-of-Phase 2 meeting between the IND sponsor and the FDA?
• What does "labeling" refer to in drug regulation?
• What does "fast track designation" enable for certain drugs?
• How many days after the start of the DCP Assessment Step I should the reference member state supply the draft labeling?
• What is the BEST source for determining the format of a MAA intended for submission to a health authority?
• A drug with accepted medical use but limited potential for abuse is likely classified under which controlled substance schedule?
• In case of a specification deviation leading to a product recall, what activity is the regulatory professional MOST closely involved in?
• A company is developing an unapproved drug-device combination product. What application type should they submit?
• What is the primary purpose of the FDA in the regulatory process for drugs?
• Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
• Which of the following is NOT true about human factors (HF) validation studies for drug-led combination products?
• If a clinical investigator wants to treat a gravely ill patient outside of the protocol inclusion criteria, what should they do?
• If a sponsor wants to amend an existing protocol during an early-stage IND for an oncology drug trial, what is the best advice to give regarding reporting requirements?
• Which of the following pairs of blenders would be considered least likely to impact product quality when changed?
• What is the primary purpose of a clinical trial submission to a regulatory authority?
• A firm is preparing a 510(k) for a microhematocrit analyzer. To whom should the submission be addressed?
• What is the most appropriate indication to present in sales materials when consulting with a regulatory professional about using the same materials in multiple countries?
• What is involved in post-marketing surveillance?